



Toxicology for Pharmaceutical and Regulatory Scientists

March 30–April 3, 2020

Gaithersburg Marriott Washingtonian Center
Gaithersburg, Maryland, United States

Course Description

This annual ACT course provides basic training in general toxicology. Using pharmaceutical development as an example, participants will obtain an overall understanding of the principles of toxicology and nonclinical safety evaluation. The course will include discussion of regulatory case studies and hands-on analyses of nonclinical data. The course is intended to benefit individuals working with small and large molecules from biotechnology and pharmaceutical companies, CROs, and regulatory agencies, or individuals interested in or currently practicing toxicology.

Monday, March 30

Principles of Toxicology

A. Wallace Hayes, University of South Florida,
College of Public Health

Introduction to Pharmacology for the Toxicologist

Amy Avila, US Food and Drug Administration

Principles of Drug Metabolism and Toxicokinetics and Applications to Pharmaceutical Toxicology

Debie Hoivik, Akebia Therapeutics

Safety Pharmacology for Human Pharmaceuticals

Mary Jeanne Kallman, Kallman Preclinical Consulting

Tuesday, March 31

General Toxicology

Lorrene Buckley, Eli Lilly and Company

Toxicology of Organ Systems

Mary Beth Genter, University of Cincinnati

Clinical Pathology: Principles for Pharmaceutical and Regulatory Scientists

Lila Ramaiah, Pfizer, Inc.

Pathology in Toxicology Studies

Thomas Steinbach, Experimental Pathology Laboratories, Inc.

Wednesday, April 1

Genetic Toxicology

Mark Powley, Merck & Co., Inc.

Evaluation of Potential Carcinogenicity

James Popp, Stratoxon LLC

Reproductive/Developmental and Juvenile Toxicology

Alan Hoberman, Charles River

Nonclinical Safety Evaluation of Biotechnology-Derived Therapeutics

Melanie Hartsough, Hartsough Nonclinical Consulting, LLC

Thursday, April 2

Immunotoxicology

Florence Burleson, Burleson Research Technologies, Inc. (BRT)

Risk Assessment

Melissa Rhodes, Aerami

Regulatory Toxicology—A Nonclinical Pharmacology and Toxicology Perspective

Hanan Ghantous, US Food and Drug Administration

Cell and Gene Therapy

Sandhya Sanduja, US Food and Drug Administration

Practical Application: Nonclinical Case Studies

Hanan Ghantous, US Food and Drug Administration

Friday, April 3*

Preparation of Nonclinical Documents for Regulatory Submission

Paul Nugent, Pfizer, Inc.

Review of Drug K: History and Outcome

Kenneth Hastings, Hastings Toxicology Consulting, LLC

*Course ends at noon.

Course Organizers:

Joseph Francisco, PhD, Charles River

Hanan Ghantous, PhD, DABT, US FDA

Timothy McGovern, PhD, US FDA

REGISTER ONLINE

**Early-Bird Registration
Deadline: February 3**

**Regular Registration:
February 4–March 27**

**For more course information
and to register, visit
www.actox.org**